H. Lundbeck A/S

H. Lundbeck develops, produces and markets drugs for treating diseases of the central nervous system. Products include antidepressants for the treatment of depression, panic disorder, and prevention of relapse/recurrence. Antipsychotic products for psychotic disorders; schizophrenia, anxiety, restlessness and insomnia; treatment of psychotic disorders; acute psychotic episodes, exacerbation of psychotic disorders. Co.'s products inclue Cipralex®/Lexapro® for the treatment of depression and anxiety; Ebixa® for the treatment of Alzheimer's disease; Azilect® for the treatment of Parkinson's disease; Xenazine®, Sabril®, Saphris® Sycrest®, Onfi, and other.
  • TickerLUN
  • ISINDK0010287234
  • ExchangeNasdaq Nordic Copenhagen
  • SectorPharmaceuticals & Biotechnology
  • CountryDenmark

Analysts

Aksel Øverland Engebakken ...
  • Jan Erik Gjerland
  • Jannick Lindegaard Denholt
  • Morten Raunholt Eismark
  • Stefan Knutsson

Talking Points - Novo Nordisk (Hold): What to expect from the upcoming CMD?

Ambu (Sell) Post-results: Yet another round of big strategic changes …will shed light on the entire business, but key focus… …to be on Rybelsus and Region IO growth prospects

Benjamin Silverstone ...
  • Jannick Lindegaard Denholt

Lundbeck - Will investor day ease the growth headache?

Lundbeck to host an investor event on 19 November… …to provide an update on its corporate strategy Progress has been made, but many questions remain

Lundbeck(H) A S: 1 director maiden bought

A director at Lundbeck(H) A S maiden bought 1,225 shares at 246.200DKK and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The name...

For H LUNDBECK A/S, the environment deterioration entails a downgrade to Neutral

H LUNDBECK A/S (DK), a company active in the Pharmaceuticals industry, now shows a lower overall rating. The independent financial analyst theScreener just confirmed the fundamental rating of 3 stars out of 4, as well as the stock market behaviour of the title as moderately risky. However, environmental deterioration penalises the general evaluation, which is downgraded to Neutral. As of the analysis date November 8, 2019, the closing price was DKK 242.50 and its expected value was estimated at DKK 232.97.

Alexander Aukner ...
  • Christoffer Wang Bjørnsen
  • Frank Maaø
  • Joachim Gunell
  • Jon Masdal
  • Karl-Johan Bonnevier
  • Martin Hoang Nguyen
  • Martin Huseby Karlsen
  • Ole Martin Westgaard
  • Ole-Andreas Krohn
  • Rune Majlund Dahl

Northern Lights

Aksel Øverland Engebakken ...
  • Jan Erik Gjerland
  • Jannick Lindegaard Denholt
  • Morten Raunholt Eismark
  • Stefan Knutsson

Talking Points - Novo Nordisk (Hold): What to expect from the upcoming CMD?

Ambu (Sell) Post-results: Yet another round of big strategic changes …will shed light on the entire business, but key focus… …to be on Rybelsus and Region IO growth prospects

Benjamin Silverstone ...
  • Jannick Lindegaard Denholt

Lundbeck - Will investor day ease the growth headache?

Lundbeck to host an investor event on 19 November… …to provide an update on its corporate strategy Progress has been made, but many questions remain

Bengt Jonassen ...
  • Haakon Amundsen
  • Jannick Lindegaard Denholt
  • Karl Fredrik Schjøtt-Pedersen
  • Magnus Andersson
  • Morten Raunholt Eismark

Talking Points - EQT (Hold): Addicted to performance

Lundbeck (Hold) Post-results comment: All eyes on 2020 progress and execution Strong top-line growth and margin expansion Initiating coverage with HOLD - TP of SEK 100

Rune Majlund Dahl

Lundbeck (Buy, TP: DKK290.00) - Strategic brands drive up guidance

Q3 revenue was slightly below our estimate, but key products sales beat our forecast by c3%, driving a guidance raise on the top line and earnings. The Q3 EBIT miss was partly due to a DKK55m admin cost related to the Alder acquisition, which we had booked in Q4, and still-high SG&A costs. Consensus does not factor in additional Alder-related SG&A costs in 2020, but we have raised our 2019–2020 forecasts and upped our target price to DKK290 (270). We reiterate our BUY.

Benjamin Silverstone ...
  • Jannick Lindegaard Denholt

Lundbeck - All eyes on 2020 progress and execution

Progressing well, but not a slam-dunk yet However, raised FY’19 guidance bodes well for the future HOLD maintained and TP unchanged at DKK 235

Lundbeck(H) A S: 1 director maiden bought

A director at Lundbeck(H) A S maiden bought 1,225 shares at 246.200DKK and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The name...

Alexander Aukner ...
  • Christoffer Wang Bjørnsen
  • Frank Maaø
  • Joachim Gunell
  • Jon Masdal
  • Karl-Johan Bonnevier
  • Martin Hoang Nguyen
  • Martin Huseby Karlsen
  • Ole Martin Westgaard
  • Ole-Andreas Krohn
  • Rune Majlund Dahl

Northern Lights

Martin Arnell ...
  • Nicolay Dyvik
  • Niklas Wetterling
  • Ole-Andreas Krohn
  • Patrik Ling
  • Rune Majlund Dahl

Northern Lights

Jørgen Lian ...
  • Martin Arnell
  • Mats Bye
  • Ole-Andreas Krohn
  • Patrik Ling
  • Rune Majlund Dahl
  • Simen Mortensen

Northern Lights

Christoffer Wang Bjørnsen ...
  • Håkon Astrup
  • Jesper Ingildsen
  • Ole-Andreas Krohn
  • Rune Majlund Dahl
  • Viktor Trollsten

Northern Lights

Håkon Astrup ...
  • Jon Masdal
  • Marius Knudssøn
  • Martin Huseby Karlsen
  • Mattias Holmberg
  • Ole Martin Westgaard
  • Ole-Andreas Krohn
  • Rune Majlund Dahl

Northern Lights

For H LUNDBECK A/S, the environment deterioration entails a downgrade to Neutral

H LUNDBECK A/S (DK), a company active in the Pharmaceuticals industry, now shows a lower overall rating. The independent financial analyst theScreener just confirmed the fundamental rating of 3 stars out of 4, as well as the stock market behaviour of the title as moderately risky. However, environmental deterioration penalises the general evaluation, which is downgraded to Neutral. As of the analysis date November 8, 2019, the closing price was DKK 242.50 and its expected value was estimated at DKK 232.97.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Expert Corporate Governance Service (ECGS)

H.Lundbeck, March 26 2019

In general, Lundbeck is in compliance with the Danish regulations relating to organisation and procedures of the Annual General Meeting. Under ITEM 4.1, it is proposed to re-appoint Mr. Lars Soren Rasmussen as Chairman of  the board of directors. Although he is considered independent, ECGS notes that Mr. Rasmussen is currently chairing the Company's remuneration committee, which is not in accordance with its guidelines. ECGS furthermore notes a lack of female representation (22%) on the board and based on its guidelines the re-election of the chairman of the chairmanship (performing the dutie...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Int'l Compass: Global Equity Strategy

Health Care outperforming globally -- overweight; India breaking out -- add exposure With the primary global ex-U.S. indexes MSCI EAFE, MSCI EM, and MSCI ACWI ex-U.S. continuing their sideways to downward consolidation from a price perspective, the importance of Sector, Group, and stock selection is critical. • Sector and Group Opportunities. Today we put the spotlight on the Health Care Sector, which is assuming a global leadership role as it separates itself from the other international Sectors. We also focus on the Communications Sector as it has seen steady relative strength ranking (RSR...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch